TD Waterhouse Canada Inc. Has $2.78 Million Holdings in IQVIA Holdings Inc. $IQV

TD Waterhouse Canada Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,109 shares of the medical research company’s stock after selling 304 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in IQVIA were worth $2,781,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of IQV. Everpar Advisors LLC increased its position in IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after buying an additional 62 shares during the period. Private Trust Co. NA increased its position in IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares during the period. Independent Advisor Alliance raised its stake in IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after purchasing an additional 72 shares during the last quarter. Nemes Rush Group LLC boosted its holdings in IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 81 shares during the period. Finally, Penserra Capital Management LLC lifted its stake in shares of IQVIA by 10.3% in the second quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after buying an additional 90 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV opened at $225.09 on Friday. The company has a fifty day moving average price of $205.80 and a two-hundred day moving average price of $180.82. The firm has a market capitalization of $38.33 billion, a PE ratio of 30.88, a P/E/G ratio of 2.43 and a beta of 1.34. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $228.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on IQV shares. Evercore ISI lifted their price target on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. BMO Capital Markets began coverage on shares of IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price on the stock. Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Finally, Citigroup increased their target price on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $240.61.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.